Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Kozhich

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The AAPS Journal|June 8, 2017
Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case StudyHao Jiang, Alex Kozhich, Jennifer Cummings, et al.
Bioanalysis|February 27, 2016
Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matricesHeather Myler, Vangipuram S Rangan, Alex Kozhich, et al.
Leukemia Research|October 7, 2008
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsSandrine d'Argouges, Sandra Wissing, Christian Brandl, et al.
Regulatory Toxicology and Pharmacology : RTP|October 7, 2018
Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculationsJanet C Gould, Irvith Carvajal, Todd Davidson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The AAPS Journal|June 8, 2017
Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case StudyHao Jiang, Alex Kozhich, Jennifer Cummings, et al.
Bioanalysis|February 27, 2016
Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matricesHeather Myler, Vangipuram S Rangan, Alex Kozhich, et al.
Leukemia Research|October 7, 2008
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cellsSandrine d'Argouges, Sandra Wissing, Christian Brandl, et al.
Regulatory Toxicology and Pharmacology : RTP|October 7, 2018
Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculationsJanet C Gould, Irvith Carvajal, Todd Davidson, et al.
Pageof 1